Keiley Elizabeth M
General Counsel at Entasis Therapeutics Holdings Inc.; SVP & General Counsel at Oxford Immunotec Global PLC
- Sold, on record
- $191k
- Dollars the filings state
- Form 4 sales
- 4
- Latest Oct 19, 2021
- Form 144 notices
- 0
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 2
- Filed as an executive or holder
Companies
- Entasis Therapeutics Holdings Inc.General Counsel
- Oxford Immunotec Global PLCSVP & General Counsel
Sales by reason
0
Routine
4
Plan not stated
0
No plan
0
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- Oxford Immunotec Global PLC11,185 shares
- Entasis Therapeutics Holdings Inc.3,759 shares
Shares sold, every Form 4 sale on record.
Timeline
- Oct 19, 2021Plan not stated
Entasis Therapeutics Holdings Inc.
Sold 7.5% of their holdings
$12k3,759 shares at $3.19
- Mar 4, 2019Plan not stated
Sold 13.2% of their holdings
$70k4,100 shares at $17.00
- Jun 15, 2017Plan not stated
Sold 13.9% of their holdings
$61k4,085 shares at $15.01
- Mar 20, 2017Plan not stated
Sold 11.8% of their holdings
$48k3,000 shares at $16.05
4 of 4
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jul 11, 2022 | Jul 11, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | OtherStock Option (right to buy) | 70,833 | 0 | SEC | ||
| Jul 11, 2022 | Jul 11, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | Returned to the company | 150,000 | 0 | SEC | ||
| Jul 7, 2022 | Jul 11, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | Tendered | 17,572 | $2.20 | $39k | 0 | SEC |
| Jan 18, 2022 | Jan 19, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | Awarded | 125,000 | 167,572 | SEC | ||
| Nov 2, 2021 | Nov 3, 2021 | Entasis Therapeutics Holdings Inc. | General Counsel | Withheld for tax | 3,669 | $2.94 | $11k | 42,572 | SEC |
| Oct 19, 2021 | Oct 20, 2021 | Entasis Therapeutics Holdings Inc. | General Counsel | Sold | 3,759 | $3.19 | $12k | 46,241 | SEC |
| Oct 19, 2021 | Oct 20, 2021 | Entasis Therapeutics Holdings Inc. | General Counsel | Awarded | 25,000 | 50,000 | SEC | ||
| Jul 16, 2021 | Feb 15, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | Returned to the companyEmployee Stock Option (Right to Buy) | 25,000 | 0 | SEC | ||
| Jul 16, 2021 | Feb 15, 2022 | Entasis Therapeutics Holdings Inc. | General Counsel | AwardedEmployee Stock Option (Right to Buy) | 20,833 | 20,833 | SEC | ||
| Jan 15, 2021 | Jan 19, 2021 | Entasis Therapeutics Holdings Inc. | General Counsel | Awarded | 25,000 | 25,000 | SEC | ||
| Jan 23, 2020 | Jan 27, 2020 | Entasis Therapeutics Holdings Inc. | General Counsel | AwardedStock Option (Right to Buy) | 50,000 | 50,000 | SEC | ||
| Mar 4, 2019 | Mar 6, 2019 | Oxford Immunotec Global PLC | SVP & General Counsel | Sold | 4,100 | $17.00 | $70k | 26,928 | SEC |
| Jan 1, 2019 | Jan 3, 2019 | Oxford Immunotec Global PLC | SVP & General Counsel | Withheld for tax | 1,605 | $12.78 | $21k | 31,028 | SEC |
| Jun 13, 2018 | Jun 14, 2018 | Oxford Immunotec Global PLC | SVP & General Counsel | Withheld for tax | 2,500 | $14.41 | $36k | 32,633 | SEC |
| Mar 15, 2018 | Mar 19, 2018 | Oxford Immunotec Global PLC | Senior VP & General Counsel | AwardedShare Option (Right to Buy) | 47,587 | 47,587 | SEC | ||
| Mar 15, 2018 | Mar 19, 2018 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Awarded | 10,882 | 35,133 | SEC | ||
| Jan 1, 2018 | Jan 3, 2018 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Withheld for tax | 1,142 | $13.97 | $16k | 24,251 | SEC |
| Jun 15, 2017 | Jun 16, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Sold | 4,085 | $15.01 | $61k | 25,393 | SEC |
| Jun 9, 2017 | Jun 13, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Withheld for tax | 1,136 | $14.63 | $17k | 29,478 | SEC |
| Mar 20, 2017 | Mar 22, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Sold | 3,000 | $16.05 | $48k | 22,429 | SEC |
| Mar 20, 2017 | Mar 22, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Exercised or settledShare Option (Right to Buy) | 11,185 | 0 | SEC | ||
| Mar 20, 2017 | Mar 22, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Exercised options | 11,185 | $0.81 | $9k | 30,614 | SEC |
| Feb 24, 2017 | Mar 6, 2017 | Oxford Immunotec Global PLC | VP & General Counsel | AwardedShare Option (Right to Buy) | 26,661 | 26,661 | SEC | ||
| Feb 24, 2017 | Mar 6, 2017 | Oxford Immunotec Global PLC | VP & General Counsel | Awarded | 5,870 | 22,429 | SEC | ||
| Mar 4, 2016 | Mar 8, 2016 | Oxford Immunotec Global PLC | VP & General Counsel | AwardedShare Option (Right to Buy) | 31,495 | 31,495 | SEC | ||
| Mar 4, 2016 | Mar 8, 2016 | Oxford Immunotec Global PLC | VP & General Counsel | Awarded | 7,559 | 16,559 | SEC | ||
| Jun 9, 2015 | Jun 11, 2015 | Oxford Immunotec Global PLC | VP & General Counsel | Awarded | 9,000 | 9,000 | SEC | ||
| Jan 16, 2015 | Jan 21, 2015 | Oxford Immunotec Global PLC | VP & General Counsel | AwardedShare Option (Right to Buy) | 9,000 | 9,000 | SEC |
Sales and notices (4)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2021 | Oct 20, 2021 | Entasis Therapeutics Holdings Inc. | General Counsel | Form 4 sale | 3,759 | $12k | 7.5% | Plan not stated | SEC |
| Mar 4, 2019 | Mar 6, 2019 | Oxford Immunotec Global PLC | SVP & General Counsel | Form 4 sale | 4,100 | $70k | 13.2% | Plan not stated | SEC |
| Jun 15, 2017 | Jun 16, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Form 4 sale | 4,085 | $61k | 13.9% | Plan not stated | SEC |
| Mar 20, 2017 | Mar 22, 2017 | Oxford Immunotec Global PLC | Senior VP & General Counsel | Form 4 sale | 3,000 | $48k | 11.8% | Plan not stated | SEC |